This memorandum summarizes the Office of the Actuary’s (OACT’s) estimates of Titles I and II of H.R. 3, “Lower Drug Costs Now Act of 2019,” which was introduced on September 19, 2019. Included are estimates of the proposal’s effects on Medicare, Medicaid, the Federal Health Insurance Marketplace, and elements of the national health expenditures. We will update this analysis to include the effects of Title III of the legislation as time permits.
Financial Impact of H.R. 3, “Lower Drug Costs Now Act of 2019”
Page Last Modified:
12/01/2021 07:02 PM